Review Article

Metilasi DNA dalam Perkembangan Kanker Kolorektal

Ni Nyoman Ayu Dewi , Ni Made Pramita Widya Suksmarini

Ni Nyoman Ayu Dewi
Biochemistry Departement, Universitas Udayana, Bali-Indonesia. Email: ayu.dewi@unud.ac.id

Ni Made Pramita Widya Suksmarini
Pre-graduate in medical school, Faculty of Medicine, Universitas Udayana, Bali-Indonesia.
Online First: June 01, 2018 | Cite this Article
Dewi, N., Widya Suksmarini, N. 2018. Metilasi DNA dalam Perkembangan Kanker Kolorektal. Intisari Sains Medis 9(2). DOI:10.15562/ism.v9i2.176


Kanker kolorektal adalah kanker yang terjadi pada kolon (usus besar) dan rektum. Kanker kolorektal menempati urutan kedua sebagai penyebab kanker di negara-negara berkembang dengan angka kematian yang tinggi. Selama ini perubahan genetik dipandang sebagai faktor paling penting dalam inisiasi dan progresivitas kanker. Namun beberapa tahun terakhir diketahui bahwa perubahan epigenetik juga memiliki peran yang sama pentingnya dengan perubahan genetik dalam perkembangan kanker. Perubahan epigenetik meliputi metilasi DNA, modifikasi histon, dan non-coding RNA. Diantara ketiga mekanisme ini, metilasi DNA adalah yang paling banyak dipelajari. Dalam artikel ini dibahas mengenai proses metilasi DNA pada sel normal dan sel kanker, khususnya kanker kolorektal. Pengetahuan dan pemahaman mengenai mekanisme epigenetik sangat diperlukan untuk kepentingan pencegahan maupun pengobatan kanker.

References

Luczak, MW., Jagodzinski, PP. 2006. The role of DNA methylation in cancer development. Folia Histochemica et Cytobiologica, 44, 143-154.

American Cancer Society. 2017. Cancer Facts & Figures 2017.

Kopetz, S., Chang, GJ, Overman, MJ., Eng, C., Sargent, DJ., Larson, DW., Grothey, A., Vauthey, JN., Nagorney, DM, McWilliams, RR. 2009. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 27, 3677–3683.

Gray R, Barnwell J, McConkey C. 2007. Adjuvant chemotherapy versus observation in patients with colorectal cancer : a randomised study. Lancet, 370 : 2020 – 2029.

Boland CR dan Goel A. 2010. Microsatellite instability in colorectal cancer. Gastroenterology, 138:2073-2087.

Guo, M.; Jia, Y. 2013. Epigenetic changes in colorectal cancer. Chin J Cancer, 32, 21-30.

Ouchi, K., Takahashi, S., Yamada, Y., Tsuji, S., Tatsuno, K., Takahashi, H., Takahashi, N., Takahashi, M., Shimodaira, H., Aburatani, H., Ishioka, C. 2015. DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Sci, 106, 1722-1729.

Lind, GE. 2005. “DNA methylation in cancer development” (tesis). Oslo: University of Oslo.

Fidianingsih, I. 2013. Metilasi CpG island gen DAPK pada leukemia limfoblastik akut. JKKI, 5, 59-68.

Chen, ZX., Mann JR., Hsieh CL. 2005. Physical and functional interactions between the human Dnmt3l protein and members of the de novo methyltransferase family. J Cell Biochem, 95:902-917.

Ballestar, E., Esteller, M. 2005. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem Cell Biol, 83: 374-384.

Mai, A. 2007. The therapeutic uses of chromatin modifying agents. Expert Opin Ther Targets, 11:835-851.

Rustgi, AK. 2007. The genetics of hereditary colon cancer. Genes Dev., 21, 2525–2538.

Feagins, LA., Souza, RF., Spechler, SJ. 2009. Carcinogenesis in IBD: Potential targets for the prevention of colorectal cancer. Nat. Rev. Gastroenterol. Hepatol., 6, 297–305.

Van Engeland, M., Derks, S., Smits, KM., Meijer, GA., Herman, JG. 2011. Colorectal cancer epigenetics: Complex simplicity. J. Clin. Oncol., 29, 1382–1391.

Zhang W, Glockner SC, Guo M. 2008. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res, 68:2764-2772.

Kim MS, Lee J, Sidransky D. 2010. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev, 29: 181-206.

Jover, R., Nguyen, TP., Perez-Carbonell, L., Zapater, P., Paya, A., Alenda, C., Rojas, E., Cubiella, J., Balaguer, F., Morillas, JD. 2011. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology, 140, 1174–1181.

Olaru, AV., Cheng, Y., Agarwal, R., Yang, J., David, S., Abraham, JM., Yu, W., Kwon, JH., Lazarev, M., Brant, SR. 2012. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers. Inflamm. Bowel Dis., 18, 641–648.

Goel A, Xicola RM, Nguyen TP. 2010. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology, 138:1854–1862.

Hibi K, Goto T, Mizukami H, Kitamura Y, Sakuraba K, Sakata M, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y. 2009. Demethylation of the CDH3 gene is frequently detected in advanced colorectal cancer. Anticancer Res, 29:2215-2217.

Estecio, MR., Gharibyan, V., Shen, L., Ibrahim, AE., Doshi, K., He, R., Jelinek, J., Yang, AS., Yan, PS., Huang, TH., Tajara, EH., Issa, JP. 2007. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One, 2, e399.

Ahn, JB., Chung, WB., Maeda, O., Shin, SJ., Kim, HS., Chung, HC., Kim, NK., Issa, JP. 2011. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer, 117, 1847–1854.


No Supplementary Material available for this article.
Article Views      : 72
PDF Downloads : 50